SCHEMBL6493882

SCHEMBL6493882

FC(F)(F)c1cc(Cl)nc(-c2ccc(Cl)cc2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.54
ALDH1A1 P00352 2/20 0.54
HSD17B10 Q99714 1/20 0.54
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45
KCNQ3 O43525 1/20 0.43
KCNQ2 O43526 1/20 0.43
MAPT P10636 3/20 0.43
ADORA2A P29274 2/20 0.43
TP53 P04637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
HIF1A Q16665 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
LMNA P02545 4/20 0.41
POLB P06746 2/20 0.41
ADORA1 P30542 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5476158 0.85 LMNA (0.58) KDM4EHSD17B10RAB9ANPC1MAPT
SCHEMBL5479399 0.84 POLB (0.47) KDM4EALDH1A1HSD17B10RAB9ANPC1
SCHEMBL6494258 0.84 NPC1 (0.44) KDM4EALDH1A1HSD17B10RAB9ANPC1
SCHEMBL5479456 0.82 HIF1A (0.42) KDM4EALDH1A1HSD17B10PTGS2ADORA2A
SCHEMBL6494121 0.82 ALDH1A1 (0.51) KDM4EALDH1A1HSD17B10RAB9ANPC1
SCHEMBL3166068 0.82 NPC1 (0.58) RAB9ANPC1MAPTTP53CYP1A2
SCHEMBL9013632 0.82 KDM4E (0.55) KDM4EALDH1A1HSD17B10PTGS1PTGS2
SCHEMBL3560817 0.81 KDM4E (0.54) KDM4EALDH1A1HSD17B10RAB9APTGS1
SCHEMBL5484106 0.81 CASP3 (0.48) HIF1A
SCHEMBL15658105 0.81 PDE4D (0.49) PTGS1PTGS2HIF1ALMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6844347-B1 Cyclic guanosine monophosphate modulators; cardiovascular diseases; guanylate cyclase activation AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-01-18 US disclosed
EP-1112266-B1 SUBSTITUTED 4-AMINO-2-ARYL-PYRIMIDINES, THEIR PRODUCTION AND USE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME AVENTIS PHARMA GMBH (DE) 2003-05-14 EP disclosed